Cancer & Hematology Centers of Western Michigan (CHCWM)’s ongoing ADRIATIC clinical trial study design and eligibility was recently published in leading academic journal, Clinical Lung Cancer. ADRIATIC is the first international phase III trial studying the benefit of immunotherapy as consolidation treatment for limited-stage small cell lung cancer patients who have completed chemotherapy and radiation. Read the study here.
CHCWM is the only West Michigan site offering the ADRIATIC trial, providing its community with access to a cutting-edge clinical trial opportunity close to home. CHCWM’s Yuanbin Chen, M.D., Ph.D. serves as the study’s principal investigator and co-author of the publication.
The global study is also sponsored by AstraZeneca, a leading international pharmaceutical company in lung cancer treatments. CHCWM participated as a leading site in AstraZeneca’s previous CASPIAN trial, as well, which was published and presented at the International Association for the Study of Lung Cancer’s 2019 World Conference on Lung Cancer in Barcelona, Spain last October. Learn more about this study and presentation here.
Founded in 1979, CHCWM has grown to become the largest physician-owned oncology and hematology practice in Michigan. We deliver advanced care in a personal way, and our expertise and caring approach make us dedicated to the help, healing and hope for cancer patients and their families. To learn more about our services and our clinics, please visit chcwm.com.
Becky Downing, Social Media & Marketing Specialist